CA
CPRX

Corrado Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Corrado Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,100
Closed -$120K – 109
2018
Q1 		$120K Sell
50,100
-11,500
-19% -$38.2K 0.07% 112
2017
Q4 		$241K Sell
61,600
-33,500
-35% -$111K 0.14% 93
2017
Q3 		$240K Sell
95,100
-41,450
-30% -$114K 0.14% 95
2017
Q2 		$377K Sell
136,550
-114,475
-46% -$239K 0.21% 76
2017
Q1 		$489K Buy
251,025
+60,425
+32% +$77K 0.28% 67
2016
Q4 		$200K Buy
190,600
+8,700
+5% +$9.94K 0.12% 99
2016
Q3 		$198K Buy
181,900
+78,600
+76% +$70.8K 0.13% 93
2016
Q2 		$73K Buy
103,300
+76,200
+281% +$61.4K 0.05% 99
2016
Q1 		$32K Buy
+27,100
New +$42K 0.02% 90
2015
Q3 		– Sell
-79,450
Closed -$328K – 67
2015
Q2 		$328K Sell
79,450
-26,250
-25% -$105K 0.15% 72
2015
Q1 		$458K Buy
+105,700
New +$381K 0.2% 57

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Corrado Advisors's CPRX Position: Q2 2018 in Review

Corrado Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2018, closing a stake of 50,100 shares — an estimated $120K sold.

Corrado Advisors first reported a position in CPRX in Q1 2015 and held it in 11 quarters. The position peaked at $489K in Q1 2017. 99 funds tracked by Wall St. Rank hold CPRX as of Q2 2018.

  • Corrado Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2018 after selling out during the quarter.
  • Corrado Advisors sold 50,100 Catalyst Pharmaceutical shares in Q2 2018, an estimated $120K.
  • Corrado Advisors first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 11 quarters.
  • Corrado Advisors's Catalyst Pharmaceutical position peaked at $489K in Q1 2017.
  • 99 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2018.

Based on Corrado Advisors's 13F filing for Q2 2018, filed 9 Jul 2018.